Page 30 - Read Online

Page 30 Kaehler et al. Cancer Drug Resist 2019;2:18-30 I http://dx.doi.org/10.20517/cdr.2019.05

2016;41:50-6.
91. Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, et al. MicroRNA-212/ABCG2-axis contributes to development of
imatinib-resistance in leukemic cells. Oncotarget 2017;8:92018-31.
92. Oberstadt MC, Bien-Moller S, Weitmann K, Herzog S, Hentschel K, et al. Epigenetic modulation of the drug resistance genes MGMT,
ABCB1 and ABCG2 in glioblastoma multiforme. BMC cancer 2013;13:617.
93. Bram EE, Stark M, Raz S, Assaraf YG. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of
acquired multidrug resistance. Neoplasia 2009;11:1359-70.
94. Reed K, Hembruff SL, Sprowl JA, Parissenti AM. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1
expression and acquisition of drug resistance. Pharmacogenomics J 2010;10:489-504.
95. To KK, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 2006;26:8572-85.
96. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, et al. ABCG2 expression, function, and promoter methylation in human multiple
myeloma. Blood 2006;108:3881-9.
97. Habano W, Kawamura K, Iizuka N, Terashima J, Sugai T, et al. Analysis of DNA methylation landscape reveals the roles of DNA
methylation in the regulation of drug metabolizing enzymes. Clin Epigenetics 2015;7:105.
98. Peng L, Zhong X. Epigenetic regulation of drug metabolism and transport. Acta Pharm Sin B 2015;5:106-12.
99. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 2010;74:149-
55.
100. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene 2014;33:3267-76.
101. Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, et al. Down-regulation of ATP-binding cassette C2 protein expression in
HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 2011;80:314-20.
102. Werk AN, Bruckmueller H, Haenisch S, Cascorbi I. Genetic variants may play an important role in mRNA-miRNA interaction: evidence
for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics 2014;24:283-91.
103. To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3’ untranslated region of its mRNA through modulation of
transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008;28:5147-61.
104. Bruhn O, Drerup K, Kaehler M, Haenisch S, Roder C, et al. Length variants of the ABCB1 3’-UTR and loss of miRNA binding sites:
possible consequences in regulation and pharmacotherapy resistance. Pharmacogenomics 2016;17:327-40.
105. He Y, Chevillet JR, Liu G, Kim TK, Wang K. The effects of microRNA on the absorption, distribution, metabolism and excretion of
drugs. Br J Pharmacol 2015;172:2733-47.
106. Zanger UM, Klein K, Kugler N, Petrikat T, Ryu CS. Epigenetics and MicroRNAs in Pharmacogenetics. Adv Pharmacol 2018;83:33-64.
107. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010;126:2-10.
108. Polkowska M, Ekk-Cierniakowski P, Czepielewska E, Kozlowska-Wojciechowska M. Efficacy and safety of BRAF inhibitors and anti-
CTLA4 antibody in melanoma patients-real-world data. Eur J Clin Pharmacol 2019;75:329-34.
109. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell
2015;161:205-14.
110. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and
network meta-analysis. BMJ 2018;363:k4226.